Physician profile
Ming Chi
NPI 1275843518
$5,488.66
in general payments reported to CMS, 2019-2025
46 companies · $1,005 in 2025
The $1,005 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,104 · 2020: $385 · 2021: $475 · 2022: $229 · 2023: $933 · 2024: $1,357 · 2025: $1,005.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,166 · Education: $128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,166.29 |
| Education | $128.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $860.06 | 2019-2025 | |
| Celgene Corporation | $401.33 | 2019-2025 | Reblozyl |
| Genentech USA, INC. | $386.30 | 2019-2024 | Lunsumio, Polivy, Rozlytrek |
| Astrazeneca Pharmaceuticals LP | $361.98 | 2019-2025 | Imfinzi, Lynparza, Enhertu |
| Merck Sharp & Dohme LLC | $280.89 | 2019-2023 | Lynparza, Keytruda |
| Janssen Biotech, INC. | $238.41 | 2022-2025 | Darzalex, Talvey, Imbruvica |
| Novartis Pharmaceuticals Corporation | $210.46 | 2019-2025 | |
| Lilly USA, LLC | $163.52 | 2019-2023 | Verzenio, Jaypirca |
| Glaxosmithkline, LLC. | $154.16 | 2020-2025 | Jemperli, Zejula, Ojjaara |
| Alexion Pharmaceuticals, INC. | $150.00 | 2020 | |
| Gilead Sciences, INC. | $149.32 | 2022-2025 | Trodelvy |
| Astellas Pharma US INC | $143.56 | 2020-2025 | Padcev |
| Seagen INC. | $141.70 | 2019-2023 | Tukysa |
| Bayer Healthcare Pharmaceuticals INC. | $135.75 | 2019-2025 | |
| Eisai INC. | $132.16 | 2022-2025 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $130.77 | 2019-2025 | Cabometyx |
| Array Biopharma INC | $119.99 | 2021-2025 | Braftovi, Tukysa, Mektovi |
| Daiichi Sankyo INC. | $118.55 | 2021-2025 | Enhertu, Datroway |
| Genzyme Corporation | $116.07 | 2019-2025 | |
| Mirati Therapeutics, INC. | $110.26 | 2023-2024 | Krazati |
| Abbvie INC. | $91.34 | 2019-2024 | Venclexta |
| Regeneron Healthcare Solutions, INC. | $80.03 | 2022-2024 | Libtayo |
| E.R. Squibb & Sons, L.L.C. | $69.24 | 2021-2025 | Opdivo, Opdualag |
| Takeda Pharmaceuticals U.S.A., INC. | $66.80 | 2024-2025 | Fruzaqla, Iclusig |
| Ipsen Biopharmaceuticals, INC | $65.21 | 2021-2024 | Onivyde |
| Puma Biotechnology, INC. | $59.75 | 2020-2024 | |
| Sobi, INC | $58.87 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $48.54 | 2019-2023 | Xarelto |
| Stemline Therapeutics INC. | $44.99 | 2023-2025 | Orserdu |
| Incyte Corporation | $43.88 | 2025 | Monjuvi |
| Foundation Medicine, INC. | $38.12 | 2019-2023 | Foundationone Liquid Cdx |
| Legend Biotech USA INC. | $36.16 | 2024 | |
| Amgen INC. | $33.27 | 2021 | |
| Taiho Oncology, INC. | $32.94 | 2024 | |
| Heron Therapeutics, INC. | $24.85 | 2019 | |
| Verastem, INC. | $23.13 | 2019 | |
| Mylan Institutional INC. | $21.84 | 2019 | |
| Beigene USA, INC. | $21.30 | 2023 | Brukinsa |
| Eusa Pharma (US) LLC | $19.30 | 2021 | |
| Clovis Oncology, INC. | $18.93 | 2019 | |
| Emd Serono, INC. | $18.21 | 2024 | |
| Servier Pharmaceuticals LLC | $15.20 | 2022 | |
| Galvanize Therapeutics, INC | $15.15 | 2024 | Aliya System |
| Deciphera Pharmaceuticals INC. | $13.67 | 2025 | Tgct, Qinlock |
| Tesaro, INC. | $11.96 | 2019 | |
| Fortovia Therapeutics, INC. | $10.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ming Chi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.